RE: Avacta Director Preclinical Development3 Nov 2022 12:25
Another sneaky, "it works " message, the little devils
Our lead pre|CISION™ FAP targeted chemotherapy agent is undergoing clinical trials. This targeted chemotherapy platform releases active drug only in the tumour, thereby limiting systemic exposure of potentially toxic anti-cancer treatments. We have several other pre|CISION™ agents in development